drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA) on plasma cells; used for multiple myeloma. CAR engagement triggers T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that binds BCMA on malignant plasma cells; CAR engagement triggers CD3ΞΆ and costimulatory signaling, leading to T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of BCMA-expressing myeloma cells.
drug_name
BCMA-directed CAR T cells
nct_id_drug_ref
NCT06630104